Sorry, no content matched your criteria.
Featured Story
Tekmira Pharma's (Nasdaq: TKMR) Stock Surges 20% as Its Ebola Drug Moves Closer to Use
Tekmira Pharmaceuticals Corp. (Nasdaq: TKMR) stock surged some 20% to $17.23 Friday after an update on its Ebola treatment.
The U.S. Food and Drug Administration modified its clinical "Hold" status on its experimental Ebola treatment to "Partial Hold," enabling it for potential use in humans infected with the virus.
Tekmira Pharmaceuticals Corp. (Nasdaq: TKMR) stock surged some 20% to $17.23 Friday after an update on its Ebola treatment.
The U.S. Food and Drug Administration modified its clinical "Hold" status on its experimental Ebola treatment to "Partial Hold," enabling it for potential use in humans infected with the virus.